Pfizer’s latest FDA rebuke is part of a much longer story
Pfizer has become the 12th pharmaceutical company this year to receive an “untitled letter” from the US Food and Drug Administration (FDA) over deceptive drug advertising. But for those who have been following the company closely, the finding was far from surprising.
The FDA determined the promotional communications for Adcetris (brentuximab vedotin), including a series of Facebook advertisements, were false or misleading.
Viewed in isolation, the letter could be dismissed as a routine regulatory matter. Untitled letters are among the FDA’s most common enforcement tools and do not carry the legal consequences associated with warning letters or formal sanctions.
In addition, the FDA’s action arrives at a moment when scrutiny of pharmaceutical promotion is increasing from multiple directions, and regulators are taking a more aggressive approach to drug advertising.
Earlier this year, FDA Commissioner Marty Makary announced a broader crackdown on misleading healthcare advertising. “It’s a new era,” he said. “We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms and taking swift action.”
Yet for Pfizer, the significance of the Adcetris letter lies less in the FDA's current enforcement stance than in the company's own history. The latest rebuke did not emerge in a vacuum.
In recent months, the company has also faced questions about promotional communications relating to Vyndamax (tafamidis), its blockbuster treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
Questions have circulated among patient advocates, including Amyloidosis Support Groups, about whether some promotional claims accurately reflect the range of treatment options available to patients as the treatment landscapes evolve.
Among the issues raised by patient advocates is Pfizer's claim that Vyndamax is the only available treatment option for patients. Advocates argue that this statement does not accurately reflect the available treatment landscape.
For a company generating billions annually from its tafamidis franchise, these are not abstract compliance questions. They go to the heart of how one of the world’s most valuable cardiovascular franchises is being sold and understood by patients and clinicians.
Such questions surrounding Pfizer's promotional practices are not new. They stretch back decades and have, on several occasions, resulted in some of the largest healthcare fraud settlements in American legal history.
The most striking example came not from a regulator but from inside the company itself. In 2007, the company settled a whistleblower lawsuit brought by former sales representative Peter Rost. The suit alleged that Pfizer subsidiaries Pharmacia & Upjohn Company, Inc. and Pharmacia & Upjohn Company LLC had promoted the human growth hormone Genotropin for unapproved uses, including anti-aging and enhancement purposes in healthy adults.
The case was part of a broader pattern of off-label promotion that regulators had been attempting to address across the industry.
A few years prior, Pfizer faced serious questions over its promotion of Celebrex (celecoxib), the pain medication at the center of broader industry controversy over the cardiovascular risks associated with the COX-2 inhibitor drug class.
Issues were raised about whether the company had adequately communicated safety risks to prescribers while continuing to market the drug aggressively.
David Graham, a whistle-blower who works in the FDA's office of drug safety, said, "The fact that the FDA says now that it's concerned about Celebrex to me is a serious signal. I would be very concerned." The episode contributed to a prolonged period of litigation and regulatory attention that would follow the drug for years.
Each of these cases unfolded in different therapeutic areas, across different regulatory environments, and under different leadership. Yet each pointed to the same underlying tension between the commercial imperative to maximize a drug market and the regulatory obligation to keep promotional claims within the boundaries of approved evidence.
That tension has never been unique to Pfizer. But Pfizer’s scale, history, and current dominance in ATTR-CM give the questions about Vyndamax communications a context that is difficult to set aside.
